Study Design
Preclinical study using multiple PKD animal models (orthologous and non-orthologous). Tested time-restricted feeding, ketogenic diet, and acute BHB administration.
Intervention
Three interventions tested: (1) Time-restricted feeding (limiting food availability), (2) Ketogenic diet (high-fat, very-low-carb), (3) Oral BHB (beta-hydroxybutyrate) supplementation.
Key Results
Ketogenic Diet: Reduced cyst growth
Ketogenic diet significantly slowed cyst growth and preserved kidney function in PKD rat models.
Time-Restricted Feeding: Reduced cyst growth
Intermittent fasting slowed PKD progression even without caloric restriction.
BHB Supplementation: Reduced cyst growth
Acute BHB administration alone was sufficient to slow cyst growth, demonstrating the ketone body itself is the therapeutic agent.
Mechanism: mTOR/AMPK pathway
Ketosis inhibits mTOR signaling and activates AMPK in cyst-lining cells, reducing proliferation and fluid secretion.
Significance
This landmark paper established the scientific foundation for all subsequent ketogenic diet research in PKD. By showing that BHB alone (not just dietary changes) could slow cyst growth, it opened the door to supplement-based approaches like KetoCitra. Published in the high-impact journal Cell Metabolism, it sparked worldwide interest in metabolic therapies for PKD.